How Does Auvelity Work and What Makes It Different?

Auvelity is a combination of two existing drugs, dextromethorphan and bupropion, that works through a fundamentally different brain pathway than the serotonin-focused antidepressants that have dominated depression treatment for decades. Rather than targeting serotonin reuptake, its primary mechanism involves blocking NMDA receptors and activating sigma-1 receptors, a pharmacological approach that borrows from the science behind ketamine’s rapid antidepressant effects. In clinical trials, measurable symptom improvement showed up as early as the first week of treatment, which is unusually fast for an oral antidepressant.

Why Two Drugs in One Pill

Dextromethorphan is a compound most people recognize as the active ingredient in over-the-counter cough medicine. It has long been known to interact with NMDA receptors in the brain, similar to ketamine, and researchers suspected it could have antidepressant properties. The problem is that the body breaks dextromethorphan down extremely quickly. An enzyme called CYP2D6 converts it into a different compound (dextrorphan) before enough of it can reach the brain to produce meaningful psychiatric effects.

That is where bupropion comes in. Bupropion, already a well-established antidepressant on its own, happens to be a potent inhibitor of CYP2D6. In one study, nearly half of participants taking bupropion shifted from normal CYP2D6 metabolism to metabolic profiles consistent with poor metabolizers, meaning their bodies processed CYP2D6-dependent drugs much more slowly.¹ By pairing dextromethorphan with bupropion, the combination dramatically increases the amount of dextromethorphan that actually stays in the bloodstream long enough to work in the brain.²

So bupropion serves a dual purpose: it provides its own antidepressant activity and it acts as a pharmacological bodyguard for dextromethorphan, slowing the enzyme that would otherwise destroy it. This is not two antidepressants simply stacked together for additive effect. The combination creates a mechanism of action that neither drug could achieve alone.

How Its Brain Mechanism Differs from Traditional Antidepressants

Most antidepressants prescribed today, including SSRIs and SNRIs, work primarily on the monoamine system. They increase the availability of serotonin, norepinephrine, or both in the spaces between neurons. That approach helps many people, but it typically takes four to six weeks to produce meaningful relief, and a substantial percentage of patients do not respond adequately.

Auvelity targets a different system. Dextromethorphan is an uncompetitive NMDA receptor antagonist and a sigma-1 receptor agonist.³ NMDA receptors are part of the glutamate system, which is the brain’s primary excitatory signaling network. When NMDA receptors are blocked in a certain way, it appears to trigger a cascade of downstream changes, including increased production of proteins involved in neuroplasticity, the brain’s ability to form and strengthen connections between neurons. Research on ketamine, which also blocks NMDA receptors, has shown that this pathway leads to rapid increases in molecules tied to neuroplasticity, and that those molecular changes are paired with fast-acting improvements in mood.⁴

The sigma-1 receptor piece adds another layer. Sigma-1 receptors are found throughout the brain and are thought to modulate how neurons handle stress and maintain their signaling capacity. They have been identified as protein targets for a potential new class of antidepressants.³ Activating them may contribute to the resilience of neural circuits involved in mood regulation.

Meanwhile, the bupropion component works through inhibition of norepinephrine and dopamine reuptake, with no clinically significant serotonergic effects.⁵ This distinguishes it from the vast majority of antidepressants, which lean heavily on serotonin. Bupropion’s dopamine and norepinephrine activity may help with motivation and energy, symptoms that serotonin-targeting drugs sometimes struggle with. The net result is that Auvelity hits multiple brain systems simultaneously: glutamate signaling, sigma-1 receptors, and the dopamine-norepinephrine system, none of which are the primary targets of SSRIs or SNRIs.

What Happened in Clinical Trials

The pivotal evidence for Auvelity came from a phase 3 trial called GEMINI. Patients with major depressive disorder were randomly assigned to receive either dextromethorphan-bupropion or a placebo for six weeks. The group taking the active drug saw their depression scores drop by about 16 points on a standard rating scale, compared to 12 points in the placebo group, a difference that was statistically significant.⁶

The speed of response was particularly striking. The drug showed statistically significant separation from placebo at week one, and the gap widened further by week two.⁶ For context, most traditional antidepressants do not reliably outperform placebo until somewhere around the four-to-six-week mark. A one-week signal is not the same as full remission at one week, but it suggests the drug is doing something faster than what serotonin-based drugs typically achieve.

An earlier randomized trial published in the American Journal of Psychiatry also demonstrated that dextromethorphan-bupropion, acting through its NMDA receptor antagonism and sigma-1 receptor agonism, could produce clinically meaningful antidepressant effects with oral dosing.⁷ Taken together, the controlled trials made a consistent case that this combination provides a real and relatively rapid benefit for people with major depression.

How Well the Effects Hold Up Over Time

Short-term trial data is encouraging, but depression is often a chronic condition, and the real question for many patients is whether an antidepressant keeps working months down the line. Two long-term, open-label studies followed patients taking dextromethorphan-bupropion for up to 12 and 15 months. Both found that the large initial drops in depression scores were maintained throughout the study period. Remission rates approached 70%, and response rates exceeded 80%.⁸

Those numbers are high relative to what is typically seen in depression treatment, where roughly a third of patients do not respond adequately to their first antidepressant and many cycle through multiple medications. Open-label studies are less rigorous than placebo-controlled trials because there is no comparison group and both patients and clinicians know which treatment is being given, which can inflate perceived benefit. Still, sustaining those response levels over more than a year suggests the drug’s effects are not simply wearing off after the initial weeks.

Side Effects and Tolerability

Across clinical trials, dextromethorphan-bupropion was generally well tolerated, with the most common adverse events rated as mild to moderate.⁸ The side-effect profile reflects what you would expect from each component. Bupropion is already known for causing dizziness, dry mouth, nausea, and insomnia in some people, and it carries a seizure risk at higher doses. Dextromethorphan at elevated blood levels can cause dizziness and nausea as well.

One thing that tends to matter to patients choosing an antidepressant is what the drug does not cause. SSRIs are notorious for sexual side effects and weight gain, two issues that lead many people to stop taking them. Bupropion has historically been considered less likely to cause either of those problems, and since Auvelity does not act on serotonin directly, it may share that advantage.⁹ That said, individual reactions vary, and the long-term side-effect picture is still being filled in as more patients take the drug outside of controlled study settings.

Because bupropion powerfully inhibits CYP2D6, anyone taking other medications processed by that enzyme should be cautious. Many common drugs, including certain beta blockers, antipsychotics, and other antidepressants, rely on CYP2D6 for metabolism. Adding Auvelity could increase blood levels of those drugs unpredictably.¹ Your prescriber should review your full medication list before starting it.

Where It Fits Among Treatment Options

For decades, the first-line approach to major depression has been an SSRI or SNRI. Those drugs work for many people, but the weeks-long wait for them to take effect and their incomplete response rates have long been frustrations for clinicians and patients alike. Ketamine and its derivative esketamine (Spravato) opened a new chapter by showing that targeting the glutamate system could produce rapid relief, but those treatments require supervised administration in a clinical setting, which limits accessibility.

Auvelity sits in an interesting middle ground. It taps into the same glutamate-related mechanisms that make ketamine effective, but it comes in a pill you take at home. A recent expert consensus panel recommended dextromethorphan-bupropion as a first-line treatment for major depression, including in patients with co-occurring anxiety symptoms.¹⁰ That recommendation is notable because new medications often start as second- or third-line options, reserved for people who have already tried and failed other treatments. Positioning it as a potential first choice reflects confidence in both its efficacy and its safety profile.

That said, “first-line” in an expert panel recommendation does not mean it is the right choice for everyone right away. Cost can be a barrier, as newer branded medications are typically more expensive than generic SSRIs. Insurance coverage varies, and some plans may require documentation that older, cheaper drugs have been tried first. The practical reality for many patients is that Auvelity becomes an option after an SSRI has failed, not instead of trying one.

Why Speed of Onset Matters More Than It Sounds

A one-week signal of improvement might seem like a marginal upgrade over waiting four to six weeks, but in the context of severe depression, that time gap has real consequences. The early weeks after diagnosis or medication change are a period of heightened vulnerability. Patients are suffering, may be unable to work, and in some cases are at risk of self-harm. Every week that a patient waits for relief while wondering whether the pill is working is a week of continued disability and distress.

Faster onset also affects adherence. One of the biggest problems with antidepressant treatment is that people stop taking their medication before it has had a chance to work, often because they feel nothing is happening and conclude the drug is not for them. If patients feel even modest improvement within the first week or two, they are more likely to stick with the treatment long enough to reach full benefit. The early efficacy signal from Auvelity’s clinical trials addresses a genuine gap in how depression treatment has worked in practice, not just in pharmacology textbooks.

The Ketamine Connection and How It Differs

Because both Auvelity and ketamine target NMDA receptors, comparisons are inevitable. But the two are quite different in practice. Ketamine and its derivative esketamine are administered via IV infusion or nasal spray in a healthcare facility, and patients must be monitored for dissociative effects afterward. These treatments tend to produce the most dramatic rapid effects but also carry risks of misuse and dissociation that require medical supervision.

Dextromethorphan blocks NMDA receptors in a less potent way than ketamine, which is part of why it can be taken as a pill at home without the dissociative episodes. It also engages sigma-1 receptors, which ketamine does not meaningfully target, and research suggests that sigma-1 activation may contribute independently to antidepressant effects.³ The trade-off is that Auvelity’s onset, while faster than SSRIs, is not as immediate as a ketamine infusion, which can produce noticeable mood changes within hours. Auvelity’s advantage is practicality and sustainability: a daily oral pill that works quickly by antidepressant standards and maintains its effects for over a year, without requiring clinic visits for every dose.

Genetic Variability and CYP2D6

One underappreciated wrinkle with Auvelity involves genetic differences in CYP2D6 activity. People carry different versions of the CYP2D6 gene, and roughly 5 to 10 percent of the population are already poor metabolizers, meaning they naturally break down CYP2D6 substrates very slowly. For these individuals, the bupropion component’s job of slowing dextromethorphan metabolism may be partly redundant, and dextromethorphan blood levels could potentially run higher than intended.

On the other end of the spectrum, a smaller percentage of people are ultra-rapid metabolizers who chew through CYP2D6 substrates faster than average. For them, bupropion’s inhibitory effect might not be enough to raise dextromethorphan levels to the therapeutic sweet spot. Pharmacogenomic testing, a simple cheek swab, can identify where someone falls on this spectrum, and some clinicians are starting to use this information to guide prescribing decisions. It is not yet standard practice for Auvelity specifically, but given how central CYP2D6 is to the drug’s design, it may become more relevant as clinical experience accumulates.

Potential Uses Beyond Depression

Auvelity was approved for major depressive disorder, but the same dextromethorphan-bupropion combination is being studied for other conditions. One active area of research is agitation in Alzheimer’s disease, a distressing symptom that current medications handle poorly. Dextromethorphan-bupropion is currently in phase 3 trials for this indication.¹¹ The rationale is that the glutamate system and sigma-1 receptors play roles in neuronal stress responses that go beyond mood regulation, potentially making this combination useful for behavioral symptoms in neurodegenerative disease.

Smoking cessation is another area where the combination has been explored, building on bupropion’s existing use for that purpose.² Whether adding dextromethorphan improves outcomes over bupropion alone for quitting smoking remains to be determined. These additional indications are still investigational, but they reflect the breadth of what glutamate-targeting and sigma-1 mechanisms may be able to address across different brain conditions. If the Alzheimer’s agitation trials succeed, Auvelity’s combination could end up being relevant to a much larger patient population than the one it was originally designed for.